Concepedia

Author

Charles H. Redfern

Sharp HealthCare Foundation

Also Known As

C H Redfern, C. H. Redfern, C. Redfern, C.H. Redfern, Charles H Redfern, Charles H. Redfern, Charles Redfern, Marijo Bilusic

88

Publications

10.5K

Citations

25

H-Index

52

Concepts

All Affiliations

Sharp HealthCare FoundationUniversity of California, San FranciscoDana-Farber Cancer InstituteMemorial Sloan Kettering Cancer CenterHematology Oncology Associates
CH

About

Charles H. Redfern is an author at Sharp HealthCare Foundation specializing in medicine, oncology, and cancer therapeutics.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

17

19

1.6K

2

Health Sciences

3

3

58

3

Allergy

1

1

65

4

Biomedical Engineering

1

1

140

5

Biomolecular Engineering

1

1

55

Charles H. Redfern

×

32

Publications

10.4K

Citations

25

H-Index

YearCitations

Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer

Philip W. Kantoff, Celestia S. Higano, Neal D. Shore,

New England Journal of Medicine

2010

5.4K

Placebo-Controlled Phase III Trial of Immunologic Therapy with Sipuleucel-T (APC8015) in Patients with Metastatic, Asymptomatic Hormone Refractory Prostate Cancer

Eric J. Small, Paul F. Schellhammer, Celestia S. Higano,

Journal of Clinical Oncology

2006

1.1K

Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low–Expressing Advanced Breast Cancer: Results From a Phase Ib Study

Shanu Modi, Haeseong Park, Rashmi K. Murthy,

Journal of Clinical Oncology

2020

786

Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial

Noel W. Clarke, Paweł Wiechno, B. Yа. Alekseev,

The Lancet Oncology

2018

405

Rucaparib or Physician’s Choice in Metastatic Prostate Cancer

Karim Fizazi, Josep M. Piulats, M. Neil Reaume,

New England Journal of Medicine

2023

380

Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study

Kenji Tamura, Junji Tsurutani, Shunji Takahashi,

The Lancet Oncology

2019

343

Targeting HER2 with Trastuzumab Deruxtecan: A Dose-Expansion, Phase I Study in Multiple Advanced Solid Tumors

Junji Tsurutani, Hiroji Iwata, Ian E. Krop,

Cancer Discovery

2020

337

Double-Blinded Randomized Study of High-Dose Calcitriol Plus Docetaxel Compared With Placebo Plus Docetaxel in Androgen-Independent Prostate Cancer: A Report From the ASCENT Investigators

Tomasz M. Beer, Christopher W. Ryan, Peter Venner,

Journal of Clinical Oncology

2007

309

Conditional expression and signaling of a specifically designed Gi-coupled receptor in transgenic mice

Charles H. Redfern, Peter Coward, Michael Degtyarev,

Nature Biotechnology

1999

175

Conditional expression of a G <sub>i</sub> -coupled receptor causes ventricular conduction delay and a lethal cardiomyopathy

Charles H. Redfern, Michael Degtyarev, Andrew T. Kwa,

Proceedings of the National Academy of Sciences

2000

168

Page 1